EP 4009948 A4 20230823 - USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
Title (en)
USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
Title (de)
VERWENDUNG VON TGF-ALPHA-POLYPEPTID ODER ANTI-TGF-ALPHA-ANTIKÖRPERN ZUR BEHANDLUNG VON ERKRANKUNGEN UND STÖRUNGEN
Title (fr)
UTILISATION DE POLYPEPTIDES TGF-ALPHA OU D'ANTICORPS ANTI-TGF-ALPHA POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES
Publication
Application
Priority
- US 201916534691 A 20190807
- US 2020045134 W 20200806
- US 201762460616 P 20170217
Abstract (en)
[origin: WO2018151811A2] The invention provides a methods of a disease or disorder in a subject by inducing a TGF alpha immune response. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example.
IPC 8 full level
A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 16/00 (2006.01); C07K 16/22 (2006.01)
CPC (source: EP US)
A61K 9/0019 (2013.01 - US); A61K 38/18 (2013.01 - EP); A61K 38/1841 (2013.01 - EP); A61K 39/395 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 35/00 (2018.01 - EP US); A61P 37/04 (2018.01 - EP); C07K 16/22 (2013.01 - EP US); C07K 16/2818 (2013.01 - EP); A61K 45/06 (2013.01 - US); A61K 2039/505 (2013.01 - EP); C07K 16/2818 (2013.01 - US); C07K 16/2827 (2013.01 - US); C07K 2317/73 (2013.01 - EP); Y02A 50/30 (2018.01 - EP)
C-Set (source: EP)
Citation (search report)
- [A] TABERNA MIREN ET AL: "Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", FRONTIERS IN ONCOLOGY, vol. 9, 20 May 2019 (2019-05-20), XP093064826, DOI: 10.3389/fonc.2019.00383
- [A] WANG CHENG ET AL: "Transforming Growth Factor Alpha (TGF[alpha]) Regulates Granulosa Cell Tumor (GCT) Cell Proliferation and Migration through Activation of Multiple Pathways", PLOS ONE, vol. 7, no. 11, 14 November 2012 (2012-11-14), pages e48299, XP093064633, DOI: 10.1371/journal.pone.0048299
- [A] IRIS KOOPMANS ET AL: "A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint", ONCOIMMUNOLOGY, vol. 7, no. 8, 24 April 2018 (2018-04-24), pages e1466016 - 11, XP055610846, DOI: 10.1080/2162402X.2018.1466016
- See also references of WO 2021026312A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018151811 A2 20180823; WO 2018151811 A3 20180927; AU 2018222735 A1 20191003; AU 2018222735 B2 20230427; CA 3053239 A1 20180823; CA 3150054 A1 20210211; EP 3583113 A2 20191225; EP 3583113 A4 20200826; EP 4009948 A1 20220615; EP 4009948 A4 20230823; US 11279753 B2 20220322; US 2019375833 A1 20191212; US 2020079843 A1 20200312; US 2022267429 A1 20220825; WO 2021026312 A1 20210211
DOCDB simple family (application)
US 2018000021 W 20180216; AU 2018222735 A 20180216; CA 3053239 A 20180216; CA 3150054 A 20200806; EP 18754645 A 20180216; EP 20849233 A 20200806; US 201916534691 A 20190807; US 201916693046 A 20191122; US 2020045134 W 20200806; US 202217684305 A 20220301